Themes / Group
Building · established relationshipLatest completed snapshot · Aug 21 · 16:11 ET

MARKET-DISCOVERED GROUP

Biotechnology Therapeutics

THE TRADER READShared activity without a clean directional read

Price direction is split across 13 measured members. Capital-flow agreement is 30%, so the basket is not yet clean.

Price breadth9 up · 2 downRelative median unavailable
Capital-flow alignment30%Price breadth is not yet confirmed by flow
Activity nowNormalActivity score 48/100 · lift 1.0×
Evidence depth2 episodesLow sample—context, not a validated playbook
EVIDENCE CLOCK

What happened, in timestamp order

0 timed events
TIMING READA causal timing read is unavailable because no material member price onset could be timestamped.

No session event has enough timestamp precision to place on the clock.

2 earlier filing context receipts

TUE, FEB 24ADMA filing documented shared operating contextproduct pipeline / R&D affecting expense · date precision only

SUN, MAR 1APGE filing documented shared operating contextproduct pipeline / R&D affecting expense · date precision only

Headline times and retained activity confirmations are point-in-time evidence. Price order is inferred from aligned 5-minute bars. Filing evidence has date precision only and is context, not an intraday catalyst claim.

01 · WHAT IS HAPPENING

The move, the flow and who is driving it

Price breadth, unusual activity and signed capital flow are separate observations
Price sequence unavailableA timestamped price sequence is unavailable.
RELATIVE CO-MOVEMENT

How the members are behaving together

Session-normalized

Observed intraday paths are not available for this group yet.

02 · WHY IT MATTERS

Why now and where the move could travel

Context and lead/lag links are evidence, not proof of causation or a forecast
WHY NOW

Verified recent context

0 items

No verified recent catalyst is attached to this move. The relationship may be market-led rather than news-led.

WHY THIS GROUP EXISTS

Shared filing context

10/13 members covered

Moderate filing support: the strongest shared 10-Q/K outlook is operating setup (near-term outlook) across APGE, CRNX, KNSA, MDGL, PCVX, PTGX, SRRK, TARS.

product pipeline / R&D affecting expense

“The increase of $46.8 million was primarily driven by further development of our zumilokibart (APG777) program, increases in personnel costs and equity-based compensation, associated with the growth in our research and development team, and increases in external-discovery related costs and other expenses, partially offset by decreases in expenses related to our APG990/APG279, APG333/APG273 and APG808 programs.”

APGE 10-K · 2026-03-02
credit / rates affecting expense

“Loss on Extinguishment of Debt As a result of the repayment of all obligations outstanding under the Ares Credit Facility (as defined in Liquidity and Capital Resources below), we have incurred prepayment penalties and wrote off the remaining unamortized debt issuance costs and discount associated with that facility, which resulted in recognition of debt extinguishment losses of $2.2 million during the three months ended September 30, 2025.”

ADMA 10-Q · 2025-11-05
credit / rates affecting interest expense

“Other Income, Net Other income, net increased $3.1 million for the three months ended June 30, 2026, compared to the three months ended June 30, 2025, primarily related to interest income earned on our cash, cash equivalents and marketable securities, partially offset by non-cash interest expense associated with our Revenue Share Agreement entered into during the second quarter of 2026.”

APGE 10-Q · 2026-08-10
CONFIRMATION NETWORK

Outsiders and cross-asset links

0 outsiders confirming

No qualified cross-asset lead/lag link is available for this group.

Filing-linked outsiders test whether the move is spreading beyond the established cohort.

BMRNNot confirming

SRRK · text peer

NBIXNot confirming

CRNX · text peer

ROIVNot confirming

PTGX · text peer

HRMYNot confirming

CRNX · text peer

03 · WHO IS IN IT

Member participation

Unusual activity and daily price direction are shown separately
APGECRNXASNDTARSPCVXMDGLADMAARGXIONSGMABPTGXSRRKKNSA

8/13 active9 rising · 3 falling · 1 flat

MemberUnusual activityToday's moveRead now
APGEApogee Therapeutics, Inc.
Most unusual · 100/100
-0.0%
Active; unclassifiedActive in 47.4% of observed group sessions
CRNXCrinetics Pharmaceuticals, Inc.
Elevated · 68/100
+0.0%
Active; unclassifiedActive in 15.8% of observed group sessions
ASNDAscendis Pharma A/S
Elevated · 54/100
-0.4%
Active; unclassifiedActive in 26.3% of observed group sessions
TARSTarsus Pharmaceuticals, Inc.
Elevated · 30/100
+1.9%
Flow confirmerActive in 57.9% of observed group sessions
PCVXVaxcyte, Inc.
Elevated · 23/100
+2.1%
Active; unclassifiedActive in 36.8% of observed group sessions
MDGLMadrigal Pharmaceuticals, Inc.
Elevated · 23/100
-0.6%
Flow confirmerActive in 21.1% of observed group sessions
ADMAADMA Biologics, Inc.
Elevated · 23/100
+0.9%
Active; unclassifiedActive in 10.5% of observed group sessions
ARGXargenx SE
Elevated · 22/100
+0.2%
Flow confirmerActive in 10.5% of observed group sessions
IONSIonis Pharmaceuticals, Inc.
Quiet · 21/100
+1.8%
Watch / laggardActive in 0% of observed group sessions
GMABGenmab A/S
Quiet · 21/100
+0.1%
Watch / laggardActive in 15.8% of observed group sessions
PTGXProtagonist Therapeutics, Inc.
Quiet · 21/100
+2.5%
Watch / laggardActive in 57.9% of observed group sessions
SRRKScholar Rock Holding Corporation
Quiet · 19/100
+2.4%
Watch / laggardActive in 26.3% of observed group sessions
KNSAKiniksa Pharmaceuticals International, plc
Quiet · 8/100
+0.8%
Watch / laggardActive in 10.5% of observed group sessions
View exact member values
TICKERCompanyRole nowTodayObserved historyTrader interpretation
APGEApogee Therapeutics, Inc.Most unusual-0.0%47.4% of 19 sessionsMost unusual activity in this snapshot; performance direction may differ.
CRNXCrinetics Pharmaceuticals, Inc.Participating+0.0%15.8% of 19 sessionsPrice participation is not yet confirmed by per-name flow.
ASNDAscendis Pharma A/SParticipating-0.4%26.3% of 19 sessionsPrice participation is not yet confirmed by per-name flow.
TARSTarsus Pharmaceuticals, Inc.Participating+1.9%57.9% of 19 sessionsPrice participation with accumulating signed flow.
PCVXVaxcyte, Inc.Participating+2.1%36.8% of 19 sessionsPrice participation is not yet confirmed by per-name flow.
MDGLMadrigal Pharmaceuticals, Inc.Participating-0.6%21.1% of 19 sessionsPrice participation with accumulating signed flow.
ADMAADMA Biologics, Inc.Participating+0.9%10.5% of 19 sessionsPrice participation is not yet confirmed by per-name flow.
ARGXargenx SEParticipating+0.2%10.5% of 19 sessionsPrice participation with accumulating signed flow.
IONSIonis Pharmaceuticals, Inc.Quiet / lagging+1.8%0% of 19 sessionsNot participating yet; a breadth test or a genuine divergence.
GMABGenmab A/SQuiet / lagging+0.1%15.8% of 19 sessionsNot participating yet; a breadth test or a genuine divergence.
PTGXProtagonist Therapeutics, Inc.Quiet / lagging+2.5%57.9% of 19 sessionsNot participating yet; a breadth test or a genuine divergence.
SRRKScholar Rock Holding CorporationQuiet / lagging+2.4%26.3% of 19 sessionsNot participating yet; a breadth test or a genuine divergence.
KNSAKiniksa Pharmaceuticals International, plcQuiet / lagging+0.8%10.5% of 19 sessionsNot participating yet; a breadth test or a genuine divergence.

04 · HAS THIS HAPPENED BEFORE

Identity history versus measured outcomes

Structural recurrence is not the same as a validated trading outcome
POINT-IN-TIME LIVE OUTCOMES

Observed follow-through

5/5 events completed
30 minutes+0.26%100% continuation · n=3Median MFE +0.71% · MAE -0.19%
60 minutes+0.28%100% continuation · n=3Median MFE +0.71% · MAE -0.19%
Session close+0.03%50% continuation · n=2Median MFE +0.63% · MAE -0.56%
Next-session close+0.28%67% continuation · n=3Median MFE +0.71% · MAE -0.19%
Only point-in-time live watcher observations and conservative same-day EOD observations are included. Later backfills and replay runs are excluded.
Low structural sample

Only 2 completed episodes across 19 active sessions; treat history as context, not a validated playbook. These episode counts describe recurrence; the outcome ledger above is the only forward-performance evidence.

Structural support26 daysHow often the cohort identity was observed
Completed episodes2Separate periods of broad group activity
Active sessions19Completed session observations, not trades
2026-07-28 → 2026-08-2012 active sessionsNo name was active through every recorded session
2026-07-13 → 2026-07-237 active sessions6.7% composition consistency through the episode
MEMBER CONSISTENCY IN OBSERVED ACTIVE SESSIONS
PTGX57.9% · 2 episodes
TARS57.9% · 2 episodes
APGE47.4% · 1 episode
PCVX36.8% · 2 episodes
ASND26.3% · 1 episode
SRRK26.3% · 1 episode
MDGL21.1% · 2 episodes
CRNX15.8% · 1 episode
GMAB15.8% · 2 episodes
ADMA10.5% · 1 episode
ARGX10.5% · 1 episode
KNSA10.5% · 2 episodes
IONS0% · 0 episodes